Axonics (AXNX) Scheduled to Post Earnings on Monday

Axonics (NASDAQ:AXNX) is scheduled to issue its quarterly earnings data on Monday, April 29th.

Axonics (NASDAQ:AXNX) last announced its quarterly earnings results on Wednesday, February 28th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.07. The business had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative net margin of 1.66% and a negative return on equity of 1.00%. Axonics’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same period last year, the company posted $0.01 EPS. On average, analysts expect Axonics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Axonics Price Performance

Shares of NASDAQ:AXNX opened at $66.69 on Friday. The company has a market capitalization of $3.40 billion, a price-to-earnings ratio of -512.96 and a beta of 0.56. The firm’s 50 day simple moving average is $67.90 and its 200 day simple moving average is $62.77. Axonics has a fifty-two week low of $47.59 and a fifty-two week high of $69.68.

Insiders Place Their Bets

In other Axonics news, CFO Kari Leigh Keese sold 3,489 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $236,344.86. Following the completion of the sale, the chief financial officer now directly owns 43,323 shares in the company, valued at $2,934,700.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Axonics news, EVP John Woock sold 15,899 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $1,076,998.26. Following the completion of the sale, the executive vice president now directly owns 77,403 shares in the company, valued at $5,243,279.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kari Leigh Keese sold 3,489 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $236,344.86. Following the sale, the chief financial officer now owns 43,323 shares of the company’s stock, valued at $2,934,700.02. The disclosure for this sale can be found here. Insiders sold 65,837 shares of company stock worth $4,459,798 over the last three months. Insiders own 1.85% of the company’s stock.

Analysts Set New Price Targets

AXNX has been the topic of a number of analyst reports. Wells Fargo & Company reiterated an “equal weight” rating and issued a $71.00 price target (up from $68.00) on shares of Axonics in a research report on Wednesday, January 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $71.00 target price on shares of Axonics in a research note on Thursday, February 29th. CL King reaffirmed a “neutral” rating on shares of Axonics in a research note on Friday, January 12th. Needham & Company LLC restated a “hold” rating on shares of Axonics in a report on Wednesday, January 17th. Finally, Truist Financial restated a “hold” rating and issued a $71.00 price objective (down previously from $73.00) on shares of Axonics in a report on Friday, January 12th. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $70.73.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.